Datavault AI just posted its first-ever profitable quarter. Full-year 2025 revenue grew 1,362% to $39 million. The company is guiding to $200 million in 2026. The stock is trading around $0.75. Maxim Group has a $4 price target. Either this is massively mispriced or the market is reading something the press releases don’t say clearly.
Here’s what the financials actually show.
From Wireless Speakers to Data Monetization
Datavault AI started life as WiSA Technologies — the company behind the wireless audio standard in your soundbar. WiSA ended up in 300+ TV and speaker integrations with brands like LG, Klipsch, and Bang & Olufsen. Real technology. Small business.
In February 2025, management rebranded to Datavault AI Inc. and pivoted into two areas: real-world asset (RWA) tokenization / data monetization, and live event production. They acquired CompuSystems Incorporated (CSI), which handles logistics and registration for major trade shows, and API Media for live event production. Those two acquisitions explain the $5.9M in live event production revenue that showed up in 2025.
The WiSA consumer audio business contributed another $3.2M. Patent license revenue contributed $30M. That last number is where the story gets interesting — and where the risk is buried.
The Scilex Connection
Seventy-seven percent of Datavault’s 2025 revenue — $30 million out of $39.09 million — came from “patent license revenue from related parties.” The related party is Scilex Holding Company, a specialty pharmaceutical firm.
In 2024, Datavault inked a $10M worldwide exclusive license agreement with Scilex for RWA tokenization. Scilex then agreed to a $150M strategic investment in Datavault, subject to shareholder approval. That investment is still pending as of the Q4 print.
This relationship drove the entire financial transformation. It also means Datavault’s revenue base is almost entirely one deal with one related party. That’s the central tension in any DVLT analysis, and it’s the thing most of the bullish coverage glosses over.
Q4 2025: What the Numbers Say
Q4 2025 was genuinely impressive on a standalone basis:
- Revenue: $33.8M — up 3,650% year-over-year from less than $1M in Q4 2024
- GAAP Operating Profit: $4.2M (vs. a $6.3M loss in Q4 2024)
- Net Profit: $661K — first in company history
- Adjusted EBITDA: $8.1M
Full-year 2025 picture:
- Total revenue: $39.09M (vs. $2.67M in 2024)
- Net loss: $78.99M (Q1-Q3 losses were steep before Scilex revenue hit in Q4)
- Working capital: $115M+
- Debt: substantially eliminated
- Stockholders’ equity: $237.97M
- Shares outstanding: 573.4M
That last number deserves its own section.
The Dilution Math Nobody Leads With
At the end of 2024, Datavault had 52 million shares outstanding. At the end of 2025: 573.4 million. That’s a 1,001% increase in 12 months.
Share count went up 10x. Revenue went up 14x. Net loss was still $78.99M for the year. That’s not necessarily disqualifying for a growth-phase company — dilution is how pre-revenue businesses fund themselves. But it’s the single most important thing to understand before buying DVLT.
The pending Scilex $150M investment, when it closes, will almost certainly bring further dilution. The NYIAX exchange acquisition that management announced — a blockchain-enabled platform for trading tokenized data assets — is also likely dilutive. Every new dollar of capability costs equity.
Unlike KULR Technology, which went through a similar dilution cycle but had tangible hardware revenue as a floor, Datavault’s revenue base is almost entirely a licensing agreement that can be renegotiated.
Can They Hit $200M in 2026?
Management guided to $200M in 2026 revenue — roughly 400% growth from the $39M 2025 base. The Q4 annualized run rate is $135M ($33.8M x 4). Getting to $200M requires at least one of the following:
- The Scilex relationship expands significantly beyond the current $10M license deal
- New third-party enterprise licensing deals close
- NYIAX generates meaningful exchange transaction volume once acquired
- The supercomputer infrastructure (described as “under construction” on the earnings call) drives new AI compute contracts
Exchange businesses are notoriously hard to scale — you need buyers and sellers simultaneously, and that network effect takes years to build. NYIAX has the infrastructure. Whether it has the liquidity is a different question.
The company also has 63 full-time employees. Running a $200M revenue business with 63 people is possible for a capital-light IP licensing model. It’s a stretch for an exchange + live events + consumer audio + AI compute hybrid.
Bull Case
The IP is real. WiSA’s 300+ integrations with major consumer electronics brands represent actual patents and actual licensing relationships. The patent portfolio isn’t theoretical — it’s already been monetized via Scilex.
The balance sheet is clean. $115M+ in working capital with debt substantially eliminated means Datavault isn’t one bad quarter from emergency dilution. Compare that to most sub-$1 microcaps, where the bank account is the existential risk.
The first profitable quarter happened. It took 15 years and a lot of dilution, but GAAP net income of $661K in Q4 2025 is real. The adjusted EBITDA of $8.1M shows the licensing model can generate cash at scale.
Maxim Group targets $4. The analyst maintained Buy and raised the target from $3 to $4 on January 5, 2026. At $0.75, that’s 433% upside if the thesis plays out.
RWA tokenization is attracting real money. Major institutions are building infrastructure to tokenize real-world assets. Datavault’s combination of patent licensing + exchange infrastructure positions it as a potential toll-booth in that buildout — similar to how infrastructure plays in the AI power buildout have attracted premium valuations.
Bear Case
One customer is not a business. $30M of $39M revenue is Scilex. No new enterprise licensing customers have been publicly announced. Until that changes, every bullish projection is really a projection about one pharmaceutical company’s willingness to keep paying.
The stock already went to $9 and came back to $0.28. DVLT’s 52-week range is $0.28 to $9.25. The market priced in the Scilex announcement, ran it up, and then sold it back to nothing when the revenue didn’t materialize fast enough. A second hype cycle is possible. So is another 70% drawdown.
Shares outstanding rose 10x in a year. Even if revenue hits $200M in 2026, per-share economics are very different at 600M+ shares than at the 52M shares that existed in 2024. Dilution math matters.
Enterprise value is steep for the execution risk. At $0.75 with 573M shares, market cap is roughly $430M. The $200M revenue target makes the 2026 forward multiple more reasonable — but only if management actually delivers. Missing that target would reprice this significantly lower.
For context, market indifference to strong earnings is a recurring problem for small caps — CPRX beat Q4 by 61% and went nowhere. Datavault has the opposite problem: the market already gave it credit for a future it hasn’t built yet.
Verdict
DVLT at $0.75 is a speculative position, not a value play. The bull case requires believing four things simultaneously: the Scilex relationship holds and expands, new enterprise licensing deals emerge, the NYIAX exchange gets traction, and management can execute a $200M business with 63 people and no track record at that scale.
If those things happen, Maxim’s $4 target doesn’t look crazy — the IP portfolio plus exchange infrastructure would command a real revenue multiple.
The bear case is simpler: one customer, massive dilution, no announced new enterprise deals, and a stock that already went from $9 to $0.28 once. Watch Q1 2026 earnings (expected late May). That print will show whether the $200M target has any foundation — or whether Q4 was a one-time Scilex recognition event rather than the start of a real platform business.
This is not financial advice. Do your own research. I hold no position in DVLT.